Metrics as of 10/14/2026, 08:38 PM (Berlin time), refresh in progress.
Bachem Holding AG
Bachem Holding AG is a company in the healthcare sector operating within the biotechnology industry. Headquartered in Bubendorf, Switzerland, the company functions as a subsidiary of Ingro Finanz AG. With 2,725 employees, the firm serves pharmaceutical and biotechnology companies on a global scale. The core business…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
1D
+2.0%
1W
+2.3%
1M
+7.6%
6M
+12.7%
YTD
+37.4%
1Y
+47.6%
2Y
+19.9%
5Y
-50.9%
10Y
+335.4%
Next earnings date
04/03/2027 (in 138 days)
Volatility around earnings
~76% stronger price swings than usual
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
P/E
41.36
P/B
4.27
EV/EBITDA
33.36
RETURN ON EQUITY
3.5%
NET MARGIN
15.4%
DEBT/EQUITY
0.14
DIVIDEND YIELD
1.1%
AS OF
30/06/2026
FREE FLOAT
41.4%
FLOAT SHARES
30,986,445
AVG. DAILY VOLUME (30D)
92,862
Bachem Holding AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Anne-Kathrin Stoller, the company employs around 2,725 people.
The IPO was on 17/07/1998; the stock trades on SIX under the ticker BANB.SW.
The next earnings date is 04/03/2027.
Around past earnings, price swings were roughly 76% stronger than usual.
Yes. The last dividend was CHF 0.90 per share, ex-date 04/05/2026, paid on 06/05/2026.
The dividend yield is 1.1% (as of 30/06/2026).
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
Clicking "Analyze stock" lets five strategies assess Bachem Holding against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.